Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 13/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 2/20 | 0.41 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.40 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.40 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.40 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.40 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.40 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.40 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243563 | 0.82 | PSMB5 (0.47) | PSMB5CLPPPSMB1PSMB2 | |
| SCHEMBL606052 | 0.82 | ALDH1A1 (0.46) | CAPN1CA1CA2ALDH1A1HDAC3 | |
| SCHEMBL10245379 | 0.78 | PSMB5 (0.66) | PSMB5 | |
| SCHEMBL3165538 | 0.76 | PSMB5 (0.64) | PSMB5PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL10246320 | 0.76 | PSMB5 (0.52) | PSMB5CLPPPSMB1PSMB2 | |
| SCHEMBL3164575 | 0.75 | PSMB5 (0.62) | PSMB5CLPP | |
| SCHEMBL3161960 | 0.74 | PSMB5 (0.69) | PSMB5PSMB1PSMB2ALDH1A1 | |
| SCHEMBL8295006 | 0.74 | PSMB5 (0.54) | PSMB5PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL3259868 | 0.74 | PSMB5 (0.54) | PSMB5PSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL3160443 | 0.73 | PSMB5 (0.65) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885CAPN1 181/4885CA1 902/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885CAPN1 181/4885CA1 902/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885CAPN1 181/4885CA1 902/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885CAPN1 181/4885CA1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.